Prometheus Biosciences (RXDX) Competitors

Zai Lab (NASDAQ:ZLAB) and Prometheus Biosciences (NASDAQ:RXDX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.

Is ZLAB or RXDX more profitable?

Zai Lab has a net margin of -156.07% compared to Zai Lab's net margin of -3,768.76%. Zai Lab's return on equity of -33.50% beat Prometheus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-156.07%	-38.48%	-32.78%
Prometheus Biosciences	-3,768.76%	-33.50%	-29.59%

Does the MarketBeat Community favor ZLAB or RXDX?

Prometheus Biosciences received 110 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 70.64% of users gave Prometheus Biosciences an outperform vote while only 62.50% of users gave Zai Lab an outperform vote.

Company	Underperform	Outperform
Zai Lab	Outperform Votes 210 62.50%	Underperform Votes 126 37.50%
Prometheus Biosciences	Outperform Votes 320 70.64%	Underperform Votes 133 29.36%

Which has stronger earnings & valuation, ZLAB or RXDX?

Prometheus Biosciences has lower revenue, but higher earnings than Zai Lab. Prometheus Biosciences is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$251.80M	9.20	-$443.29M	-$4.09	-5.73
Prometheus Biosciences	$6.81M	1,403.55	-$141.75M	-$3.52	-56.80

Do insiders and institutionals have more ownership in ZLAB or RXDX?

43.7% of Zai Lab shares are held by institutional investors. Comparatively, 92.7% of Prometheus Biosciences shares are held by institutional investors. 5.2% of Zai Lab shares are held by insiders. Comparatively, 3.4% of Prometheus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts recommend ZLAB or RXDX?

Zai Lab presently has a consensus price target of $83.10, suggesting a potential upside of 259.74%. Prometheus Biosciences has a consensus price target of $162.70, suggesting a potential downside of 18.62%. Given Prometheus Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Prometheus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Prometheus Biosciences	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30

Does the media favor ZLAB or RXDX?

In the previous week, Zai Lab had 1 more articles in the media than Prometheus Biosciences. MarketBeat recorded 1 mentions for Zai Lab and 0 mentions for Prometheus Biosciences. Prometheus Biosciences' average media sentiment score of 1.87 beat Zai Lab's score of 0.77 indicating that Zai Lab is being referred to more favorably in the media.

Company	Overall Sentiment
Zai Lab	Very Positive
Prometheus Biosciences	Positive

Which has more volatility and risk, ZLAB or RXDX?

Zai Lab has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Prometheus Biosciences has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.

Summary

Zai Lab beats Prometheus Biosciences on 9 of the 17 factors compared between the two stocks.